One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.

PARP inhibitor treatment can induce various resistance mechanisms, including re-activating BRCA mutations, mutations in HR-inhibiting genes and upregulation of drug efflux pumps. Clinical ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for ... naïve metastatic castration-resistant prostate cancer (mCRPC) whose disease ...

The inclusion criteria were as follows (1): Histologically confirmed epithelial ovarian cancer (2); Patients received surgery combined with platinum-containing chemotherapy as first-line treatment (3) ...

The study, published today as a Reviewed Preprint in eLife, is described by the editors as a fundamental insight into overcoming treatment resistance in hormone receptor-positive (HR+) breast cancer.

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

Immune checkpoint inhibitors (ICIs) have revolutionized treatment for several tumor indications without demonstrated benefit for ovarian cancer patients. To improve the therapeutic ratio of ICIs in ...

This study aimed to develop curcumin-loaded maltodextrin-based proniosomes (CMPNs) and to evaluate their therapeutic efficacy against gemcitabine-resistant CCA both in vitro and in vivo. We focused on ...